Abstract
Drug prices are regulated in a legal framework that organizes the negotiation between pharmaceutical firms and a third-party payer responsible for healthcare reimbursement. This regulation aims at compensating for market failures associated with drug specificities. Explicit economic reasoning through the so-called health technology assessment framework is increasingly embedded in the institutional and administrative process of the evaluation procedure leading to market access, pricing and reimbursement for new drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Arrow K (1963) Uncertainty and the welfare economics of medical care. Am Econ Rev 53:941–973
Chalkidou K, Tunis S, Lopert R, Rochaix L, Sawicki P, Nasser M, Xerri B (2009) Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 87:339–367
Drummond M, Sculpher M, Claxton K, Stoddart G , Torrance G (2015) Methods for the economic evaluation of health care programmes. Oxford University Press, New York
Franken M, Heintz E, Gerber-Grote A, Raftery J (2016) Health economics as rhetoric: the limited impact of health economics on funding decisions in four European countries. Value Health 19:951–956
Gerber-Grote A, Sandmann G, Zhou M, Thoren T, Schwalm A, Weigel C, Balg C, Mensch A, Mostardt S, Seidl A, Lhachimi K (2014) Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty? Z Evid Fortbild Qual Gesundhwes 108:390–396
Grossman M (1972) On the concept of health capital and the demand for health. J Polit Econ 80:223–255
Heintz E, Gerber-Grote A, Ghabri S, Hamers F, Prevolnik Rupel V, Slabe-Erker R, Davidson T (2016) Is there a European view on health economic evaluation? Results from a synopsis of methodological guidelines used in the EUnetHTA partner countries. PharmacoEconomics 34:59–76
Hurley J (2000) An overview of the normative economics of the health sector. In: Culyer A, Newhouse J (eds) Handbook of health economics. Elsevier, Amsterdam, pp 55–118
ISPOR (International Society for Pharmacoeconomics and Outcomes Research), Sullivan S, Mauskopf J et al (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17:5–14
Klingler C, Shah M, Barron J, Wright S (2013) Regulatory space and the contextual mediation of common functional pressures: analyzing the factors that led to the German efficiency frontier approach. Health Policy 109:270–280
Mauskopf J (1998) Prevalence-based economic evaluation. Value Health 1:251–259
Mauskopf J (2014) Budget-impact analysis. In: Culyer A (ed) Encyclopedia of health economics, vol 1. Elsevier, Amsterdam, pp 98–107
Mauskopf J, Earnshaw S (2016) A methodological review of US budget-impact models for new drugs. PharmacoEconomics 34:1111–1131
McCabe C, Claxton K, Culyer A (2008) The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 26:733–744
Meltzer D (1997) Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 16:33–64
Morris S, Devlin N, Parkin D (2007) Economic analysis in health care. Wiley, New York
Rice T, Rosenau P, Unruh L, Barnes A, Saltman R, van Ginneken E (2013) United States of America: health system review. Health Syst Transit 15:70–80
Sorenson C, Chalkidou K (2012) Reflections on the evolution of health technology assessment in Europe. Health Econ Policy Law 7:25–45
Walton S, Basu A, Mullahy J, Hong S, Schumock G (2017) Measuring the value of pharmaceuticals in the US health system. PharmacoEconomics 35:1–4
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this entry
Cite this entry
Josselin, JM., Jacquet, L.R., Raimond, V., Rochaix, L. (2019). Drug Price Regulation. In: Marciano, A., Ramello, G.B. (eds) Encyclopedia of Law and Economics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7753-2_714
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7753-2_714
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7752-5
Online ISBN: 978-1-4614-7753-2
eBook Packages: Economics and FinanceReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences